FDA Approves Daratumumab for Multiple Myeloma Ineligible for Autologous Stem Cell Transplant
Jun 28
2019
The Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
